German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery. The partnership leverages IBM’s foundation model technologies, consisting of pre-trained, large-scale neural network architectures, to accelerate the identification of novel antibodies vital for therapeutic … [Read more...]